Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463206 | 0.82 | PTGDR2 (0.74) | PTGDR2ERCC1ERCC5FEN1ERCC4 | |
| SCHEMBL400776 | 0.72 | PTGDR2 (0.78) | PTGDR2 | |
| SCHEMBL10074104 | 0.70 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL203679 | 0.69 | ALDH1A1 (0.61) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL8300494 | 0.69 | PLA2G2A (0.66) | PTGDR2PLA2G2AALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL25259767 | 0.68 | ALDH1A1 (0.59) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL6627880 | 0.68 | ALDH1A1 (0.43) | ALDH1A1MAPTTSHRTDP1MAPK1 | |
| SCHEMBL8292611 | 0.66 | PLA2G2A (0.60) | PLA2G2AMAPTPLA2G1B | |
| Phenylacetic Acid SCHEMBL11667819 | 0.66 | PAM (0.59) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL8301038 | 0.66 | PLA2G2A (0.71) | PTGDR2PLA2G2AALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | HRH2, HRH1, TSLP | PTGDR2 13/4885ERCC1 4244/4885ERCC5 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.